Business
Physiomics to present cardiac toxicity platform
Physiomics to present cardiac toxicity platform.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 0096O Physiomics PLC 13 September 2013 \n \n\n \n \nPhysiomics plc\nThe Magdalen Centre\nThe Oxford Science Park\nRobert Robinson Avenue\nOxford\nOX4 4GA\nUK\n \nTel 01865 784980\nFax 08701 671931\n16 September 2013 \nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics to present on the cardiac toxicity platform at the 2013 Safety Pharmacology Society's Annual Meeting (\"SPS\")\n \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform developed at Physiomics. \n \nThe platform uses readily available lab-based data to predict the risk that drugs in development will have serious cardiac side effects which could lead to drug program closure. Three versions of the model are now available, two to predict outcomes in animal experiments, dog and rabbit, and a third one to predict cardiac liability in humans. Benchmarking tests against state of the art models will be presented in the poster. The results show that the Physiomics model is more predictive than the state of the art models. Furthermore, given that the same structural model is used for making predictions in different species, the model is ideally placed to make translational predictions, i.e. from animal to human. \n \nThe abstract #23 (\"Predicting Cardiac Toxicity from Data Generated via High‐Throughput Screening\") will be presented in the \"Disease Models, In Silico, Exploratory Pharmacology\" session.\n \nMore information about the conference may be found at:\nhttp://www.safetypharmacology.org/am2013/\n \nDr Mark Chadwick, CEO of Physiomics, commented:\n\"We are delighted to present the progress of our cardio tox platform at the SPS meeting as part of our roll out of this new service, which has already attracted significant interest from our large pharma partners.\"\n \n \n \nEnquiries:\n \nPhysiomics p...